Helen M. Thackray - 15 Jun 2022 Form 4 Insider Report for ImmunoGen, Inc.

Role
Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Jun 2022
Net transactions value
+$108,062
Form type
4
Filing time
17 Jun 2022, 16:09:00 UTC
Previous filing
04 Apr 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Deferred Share Unit Award $0 +10,932 +36% $0.000000 40,932 15 Jun 2022 Common Stock 10,932 $0.000000 Direct F1, F2, F3
transaction IMGN Stock Option (right to buy) Award $108,062 +32,066 $3.37* 32,066 15 Jun 2022 Common Stock 32,066 $3.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
F2 The deferred share units vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.
F3 The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
F4 The stock options vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.